Abstract

Case Presentation

Analysis of the Factors of Therapeutic Failure after Transition to Acriptega: About Two Cases

Medard Amona*, Yolande Voumbo Mavoungou Matoumona, Hama Nemet Ondzotto, Grace Paterson Ngouaka, Benjamin Kokolo, Armel Itoua, Gilius Axel Aloumba and Pascal Ibata

Published: 20 February, 2026 | Volume 9 - Issue 1 | Pages: 001-009

Acriptega, a combination of Dolutegravir, Lamivudine, and Tenofovir, is a cornerstone of modern antiretroviral therapy due to its efficacy and tolerability. However, treatment failures persist despite this optimization, raising questions about barriers to successful treatment. Through the analysis of two clinical cases, this study explores the biological and behavioral factors contributing to these failures following a switch to this molecule.
The first case is a 69-year-old female patient, diagnosed with HIV in 2002 following pulmonary tuberculosis, who was regularly monitored with an undetectable viral load and a CD4 count > 500 cells/mm³ until the Acriptega transition and the onset of tumor symptoms in 2024. The second case is a 62-year-old female patient, diagnosed with HIV in 2009 following cerebral toxoplasmosis. She was regularly monitored with good treatment adherence and an undetectable viral load. After switching her triple therapy, she developed gastroenteritis, which led to the discovery of her treatment failure.    
This case study highlights that failure after switching to Acriptega is linked to the absence of prior resistance testing (genotyping). A safe switchover requires a rigorous assessment of the patient’s virological history to prevent the emergence of cross-resistance. Close monitoring via genotyping is essential.

Read Full Article HTML DOI: 10.29328/journal.ijcmbt.1001033 Cite this Article Read Full Article PDF

Keywords:

Transition; Therapeutic factors; Acriptega; Brazzaville; Congo

References

  1. World Health Organization. HIV drug resistance. Fact sheets. 25 Nov 2025 [Internet]. 2025 [cited 10 Feb 2026]. Available from: https://www.who.int/fr/news-room/fact-sheets/detail/hiv-drug-resistance
  2. Ministry of Health and Population (CG). Validation of the monitoring and evaluation plan for the national strategic framework for the HIV/AIDS response 2019-2022, extended to 2023. Brazzaville: Ministry of Health; 2021 [cited 10 Feb 2026]. Available from: https://sante.gouv.cg/validation-du-plan-de-suivi-evaluation-du-cadre-strategique-national-de-riposte-au-vih-sida-2019-2022-etendu-a-2023/
  3. World Health Organization. 2024 HIV Drug Resistance Report [Internet]. Geneva: WHO; 2024 [cited 10 Feb 2026]. Available from: https://www.who.int/fr/news/item/05-03-2024-new-report-documents-increase-in-hiv-drug-resistance-to-dolutegravir
  4. World Health Organization. Updates to recommendations on HIV prevention, infant diagnosis, initiation, and monitoring of antiretroviral therapy: March 2021. Geneva: World Health Organization; 2021.
  5. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706. Available from: https://doi.org/10.1056/NEJMoa0905848
  6. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1471-81. Available from: https://doi.org/10.1056/nejmoa1013911 
  7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. 154 p.
  8. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care: towards primary health care [Internet]. Geneva: WHO; 2021 [cited 10 Feb 2026]. Available from: who.in t
  9. Foulon S, Gracia-Gomez J, Ferron JF, Legoupil D, Schick U, Mondot S, et al. Immuno-radiotherapy: a review of the rationale. Bull Cancer. 2024; 111 (3): 285-300.
  10. Tokuyama M, Belzer C, Galipeau HJ, et al. Sustained gut dysbiosis and intestinal inflammation show differences between men and women with HIV on antiretroviral therapy. Common Med (Lond). 2024 Jul 24;4(1):145.
  11. Rhee SY, Shafer RW. Molecular Mechanisms of Antiretroviral Drug Resistance. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 5th ed. Washington, DC: ASM Press; 2021. p. 245-78.
  12. Rhee SY, Grant PM, Tzou JH, Barrow G, Harrigan PR, Shafer RW. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019 Nov 1;74(11):3135-3149. Available from: https://doi.org/10.1093/jac/dkz256
  13. Grabarczyk M, Wiercińska-Drapało A, Pawłowska-Boroń M, Jaroszewicz J. The Effect of Antiretroviral Therapy on SIRT1, SIRT3, and SIRT6 Expression in HIV-Infected Patients. Molecules. 2022;27(4):1358. Available from: https://doi.org/10.3390/molecules27041358
  14. Pawłowski T, Kucharska M, Paprocka-Borowicz M, Firlag-Burkacka E. The effect of antiretroviral therapy on SIRT1, SIRT3, and SIRT6 expression in HIV-infected patients. Molecules. 2022 Feb 17;27(4):1358. Available from: https://doi.org/10.3390/molecules27041358

Figures:

Similar Articles

  • Atherogenic risk assessment of naive HIV-infected patients attending Infectious Diseases Service of Kinshasa University Teaching Hospital, Democratic Republic of the Congo (DRC)
    MMK Mbula*, HNT Situakibanza, GL Mananga, B Longo Mbenza, JRR Makulo, MM Longokolo, MN Mandina, NN Mayasi, MM Mbula, B Bepouka, GL Mvumbi, EN Amaela, DN Tshilumba, O Odio, BM Ekila, A Nkodila and BT Buasa MMK Mbula*,HNT Situakibanza,GL Mananga,B Longo Mbenza, JRR Makulo,MM Longokolo,MN Mandina,NN Mayasi,MM Mbula,B Bepouka,GL Mvumbi,EN Amaela,DN Tshilumba,O Odio,BM Ekila,A Nkodila,BT Buasa. Atherogenic risk assessment of naive HIV-infected patients attending Infectious Diseases Service of Kinshasa University Teaching Hospital, Democratic Republic of the Congo (DRC). . 2020 doi: 10.29328/journal.ijcmbt.1001015; 3: 040-048
  • The Bacteriological Profile of Nosocomial Infections at the Army Central Hospital of Brazzaville
    Medard Amona*, Yolande Voumbo Matoumona Mavoungou, Hama Nemet Ondzotto, Benjamin Kokolo, Armel Itoua, Gilius Axel Aloumba and Pascal Ibata Medard Amona*,Yolande Voumbo Matoumona Mavoungou,Hama Nemet Ondzotto,Benjamin Kokolo,Armel Itoua,Gilius Axel Aloumba,Pascal Ibata. The Bacteriological Profile of Nosocomial Infections at the Army Central Hospital of Brazzaville. . 2025 doi: 10.29328/journal.ijcmbt.1001032; 8: 009-022
  • Analysis of the Factors of Therapeutic Failure after Transition to Acriptega: About Two Cases
    Medard Amona*, Yolande Voumbo Mavoungou Matoumona, Hama Nemet Ondzotto, Grace Paterson Ngouaka, Benjamin Kokolo, Armel Itoua, Gilius Axel Aloumba and Pascal Ibata Medard Amona*,Yolande Voumbo Mavoungou Matoumona,Hama Nemet Ondzotto,Grace Paterson Ngouaka,Benjamin Kokolo,Armel Itoua,Gilius Axel Aloumba,Pascal Ibata. Analysis of the Factors of Therapeutic Failure after Transition to Acriptega: About Two Cases. . 2026 doi: 10.29328/journal.ijcmbt.1001033; 9: 001-009

Recently Viewed

Read More

Most Viewed

Read More

Help ?